About 51.3% of men in Singapore over the age of 30 reported some degree of erectile dysfunction
Erectile dysfunction (ED) was linked with loss of work productivity and with lower health-related quality of life in an International Journal of Clinical Practice study of more than 52,000 men from eight countries.
In the study of men aged 40 to 70 years in Brazil, China, France, Germany, Italy, Spain, the United Kingdom, and the United States, the overall ED prevalence was 49.7%, with Italy reporting the highest rate (54.7%). Men with Erectile dysfunction reported significantly higher rates of staying home from work (7.1% versus 3.2%), working while sick (22.5% versus 10.1%), work productivity impairment (24.8% versus 11.2%), and activity impairment (28.6% versus 14.5%) than men without ED. They also had lower measures of health-related quality of life.
Contrary to popular belief that ED is a rare condition and can be embarrassing to admit, erectile dysfunction is actually more common than you think among men in Singapore.
In a study among Singapore men, it was estimated that 51.3% of men over the age of 30 reported some degree of erectile dysfunction.
Getting proper treatment for erectile dysfunction from a urologist is not only important for satisfactory sexual intercourse, but it may also be related to other medical conditions. ED is commonly seen in people with low testosterone levels, and low testosterone levels have been attributed to major conditions such as heart disease or high blood pressure.
(Read also: Heart Attack – Women wait longer than men to get help and it could prove fatal)
ED is also seen in people with diabetes and depression, so getting treatment for erectile dysfunction will also give a person a chance to see whether the underlying condition is properly managed.
“This study shows that ED remains a prevalent concern, one that impacts work productivity and absenteeism,” said co-author Wing Yu Tang, of Pfizer Inc. “Stemming from eight countries, the global coverage of the data also suggests that this issue is pervasive across geographies,” added senior author Tarek Hassan, also of Pfizer Inc.
